Healthcare Logistics Provider Owens & Minor Calls Q2 Performance Consistent With Expectations, Reiterates Annual Guidance
Healthcare Logistics Provider Owens & Minor Calls Q2 Performance Consistent With Expectations, Reiterates Annual Guidance
On Friday, Owens & Minor Inc. (NYSE:OMI) reported that the second quarter of 2024 adjusted EPS of $0.36, double the $0.18 reported a year ago, beating the consensus of $0.33.
紐交所上市公司奧文斯與米納公司（Owens & Minor Inc.）於週五發佈2024年第二季度調整後的每股收益爲0.36美元，是一年前的0.18美元的兩倍，超過了0.33美元的共識預期。
The company reported sales of $2.671 billion, up 4% year-over-year, almost in line with the consensus of $2.646 billion.
該公司報告的銷售額爲26.71億美元，同比增長4%，幾乎與26.46億美元的共識預期相符。
Patient Direct revenue of $660 million, up 4% compared to the second quarter of 2023, driven by continued strong growth in diabetes and sleep supplies.
直接患者銷售收入爲6600萬美元，比2023年第二季度增長了4%，受糖尿病和睡眠用品需求的持續強勁增長帶動。
Related: Healthcare Logistics Service Firm Owens & Minor To Buy Home-Based Care Equipment Firm For $1.4B, Sees Better Than Expected Q2 Earnings.
相關報道：醫療物流服務公司Owens & Minor以14億美元收購家庭護理設備公司，並看好第二季度的業績表現。
Products & Healthcare Services revenue of $2.0 billion, up 4% compared to the second quarter of 2023, driven by strong same-store sales and new wins in the Medical Distribution division.
產品和醫療服務收入爲20億美元，比2023年第二季度增長了4%，得益於同店銷售額的增強以及醫療分配部門的新客戶。
Operating income of $20.3 million and adjusted operating income of $76.3 million increased by 87% and 23%, respectively, in the second quarter of 2024.
2024年第二季度營業利潤爲2030萬美元，調整後的營業利潤爲7630萬美元，同比分別增長了87%和23%。
Adjusted EBITDA increased 12% to $127 million, with an operating cash flow of $116 million for the second quarter of 2024.
調整後的EBITDA增長了12％，至1.27億美元，2024年第二季度的經營現金流爲1.16億美元。
"Our second-quarter performance is consistent with our expectations, as we are in the early stages of implementing our long-term strategy discussed at Investor Day in December 2023. Our previous investments in our Products & Healthcare Services segment yielded positive results and generated top-line growth in our Medical Distribution division. Our Patient Direct segment performed in line with our expectations, and we expect the segment to benefit from seasonality and recent organic investments during the back half of the year," said Edward Pesicka, President & CEO.
公司總裁兼首席執行官愛德華·佩西卡（Edward Pesicka）表示：“我們的第二季度業績符合我們的預期，因爲我們正在實施我們在2023年12月股東日上討論的長期策略的早期階段。我們以前在產品和醫療服務部門的投資產生了積極的結果，併爲我們的醫療分配部門的營業收入增長提供了動力。我們的直接患者銷售部門表現符合我們的預期，我們預計該部門將受益於全年後半段的季節性因素和最近的有機投資。”
Guidance: Owens & Minor reaffirms 2024 revenue guidance of $10.5 billion-$10.9 billion versus the consensus of $10.665 billion.
Owens & Minor重申2024年營業收入指引爲105億至109億美元，而共識預期爲106.65億美元。
The company expects 2024 adjusted EPS of $1.40-$1.70 versus the consensus of $1.55.
該公司預計2024年每股調整後的收益爲1.40美元至1.70美元，而共識預期爲1.55美元。
Price Action: OMI stock was trading lower by 3.90% to $15.78 premarket at the last check on Friday.
截至週五上午，OMI股票預盤下跌3.90％至15.78美元。
- LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector.
- LabCorp第二季度表現出色，分析師強調其在醫療板塊中的強勢位置後其股票猛漲。